Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

The development of brain stem cells into new nerve cells and why this can lead to cancer

No. 06 | 31/01/2019

Stem cells are true "Jacks-of-all-trades" of our bodies, as they can turn into the many different cell types of all organs. This allows the tissues such as muscle or even brain to renew and to heal after injury. This amazing "multipotency" makes stem cells in the adult body key tools for the future of regenerative medicine. Scientists at the German Cancer Research Center (DKFZ) now publish in the journal "Nature" how brain stem cells make the decision to transform into new nerve cells.

TOR activity (red) in the brain of a mouse. The newly generated immature nerve cells (neuroblasts) are shown in green. The dotted line shows the "Bulbus Olfactorius", a part of the brain into which the immature nerve cells migrate.
© Ana Martin-Villalba/DKFZ

Ana Martin-Villalba and her research team at the German Cancer Research Center followed stem cells along the path to neurons. The scientists analyzed at every step which genes where switched on and which of them were actually turned into new proteins. They expected to find that stem cells would simply switch their stem cell genes entirely off in order to become a neuron. But things turned out to be much more complicated. Martin-Villalba and her co-workers found that stem cell genes were not switched off, but simply put on standby, by preventing them from making the protein product that keeps the cell multipotent.

"To go into this standby mode and thus start the journey to become a neuron, stem cells switch off their inner signal to proliferate (called TOR) and stop to divide," says Ana Martin-Villalba. Very surprisingly, the researchers also found that stem cells always buy a return ticket. Just as flights can travel back and forth between countries, switching on or off TOR allows cells to travel from stem cell to neuron or back. "Thus, the decisions of a stem cell to become a neuron, remains reversible for some time," says Avni Baser, the scientist leading this project.

Normally, the travel of stem cells is in one direction to make nerve cells, unless something goes wrong in between. But if stem cells cannot properly control their TOR signal, they keep going back to stem cells, which in the long run can cause brain cancer rather than healing the brain. Indeed, in many cancers the levels of the TOR signal is artificially high. For future developments of stem cell therapy, understanding and controlling TOR activity in stem cell will thus be very important.

Avni Baser, Maxim Skabkin, Susanne Kleber, Yonglong Dang, Gülce S. Gülcüler Balta,
Georgios Kalamakis, Manuel Göpferich, Damian Carvajal Ibañez, Roman Schefzik,
Alejandro Santos Lopez, Enric Llorens Bobadilla, Carsten Schultz, Bernd Fischer & Ana Martin-Villalba: Onset of differentiation is posttranscriptionally controlled in adult neural stem cells.
Nature 2019, DOI: https://doi.org/10.1038/s41586-019-0888-x

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS